- Market Capitalization, $K 2,983,923
- Shares Outstanding, K 128,396
- Annual Sales, $ 50,120 K
- Annual Income, $ -102,680 K
- 60-Month Beta 0.48
- Price/Sales 60.23
- Price/Cash Flow N/A
- Price/Book 6.77
|Period||Period Low||Period High||Performance|
| || |
+5.85 (+33.05%)since 08/27/21
| || |
+9.25 (+64.69%)since 06/25/21
| || |
+9.30 (+65.26%)since 09/25/20
Investors need to pay close attention to Aurinia (AUPH) stock based on the movements in the options market lately.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the "Company") today announced that members of the senior management team will present at the following upcoming virtual investor conferences:
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the "Company") today announced that members of the senior management team will participate in the H.C. Wainwright & Co. 23rd Annual Global Investment Conference,...
Aurinia (AUPH) acquires two pre-clinical, novel pipeline programs for the treatment of rare autoimmune, fibrotic and kidney diseases. Yet, the stock price declines.
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
--- IND-enabling studies are ongoing and will support the transition of these assets to clinical development in 2022/2023 -
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the "Company") today announced that members of the executive management team will participate in a fireside chat during the Virtual BTIG Annual Biotech Conference...
Aurinia (AUPH) delivered earnings and revenue surprises of -5.71% and 32.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company") today issued its financial results for the second quarter ended June 30, 2021. Amounts, unless specified otherwise, are expressed...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that it will release its second quarter 2021 financial results on Thursday, August 5, 2021, after the markets close....
|Aurinia Pharm Ord|
|Alps Medical Breakthroughs ETF|
|Invesco Nasdaq Biotechnology ETF|
|Fidelity Growth Opportunities ETF|
|Purebetasm MSCI USA Small Cap Invesco ETF|
|Nasdaq Composite ETF|
|3rd Resistance Point||24.75|
|2nd Resistance Point||24.27|
|1st Resistance Point||23.91|
|1st Support Level||23.07|
|2nd Support Level||22.59|
|3rd Support Level||22.23|